HAEMONETICS CORP — Director's Dealing 2020

Mar 10, 2020

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: HAEMONETICS CORP (HAE)
CIK: 0000313143
Period of Report: 2020-03-06

Reporting Person: Scanlan Jacqueline (SVP, Global Human Resources)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2020-03-06	Common Stock	M	1299	$38.43	Acquired	6007	Direct
2020-03-06	Common Stock	S	1299	$100.50	Disposed	4708	Direct
2020-03-09	Common Stock	S	118	$98.00	Disposed	4590	Direct
2020-03-10	Common Stock	S	207	$99.63	Disposed	4383	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2020-03-06	Non-qualified Stock Option (Right to Buy)	$38.43	M	1299	Disposed	2024-03-06	Common Stock (1299)	Direct

Footnotes

F1: Transaction pursuant to an existing 10b5-1 trading plan.

F2: This number includes unvested restricted stock units previously reported and 13 shares purchased by the reporting person under the Issuer's 2007 Employee Stock Purchase Plan (as amended) on October 31, 2019.

F3: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain restricted stock units previously reported in Table I following the date of grant. This sale is mandated by the Issuer's election under its 2005 Long Term Incentive Compensation Plan (as amended) to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

F4: Option vests in annual increments of 25% beginning on the first anniversary of the date of grant.